Q2 2026 Rxsight Inc Earnings Call Transcript
Key Points
- RxSight Inc (RXST) secured a strategic collaboration with Alcon, providing $200 million in upfront and potential milestone payments plus long-term royalties, which validates its technology and strengthens its financial position.
- The company's Light Adjustable Lens (LAL) technology is highly regarded by physicians, with many surgeons choosing it for their own family members, reflecting strong clinical confidence.
- A phase IV registry study with over 1,100 patients demonstrated strong refractive and visual outcomes, reinforcing the clinical efficacy of the LAL platform.
- RxSight Inc (RXST) plans to double its U.S. sales team to drive higher utilization and expand reach, funded by reallocating resources without significantly increasing operating expenses.
- The company ended Q2 2026 with approximately $209 million in cash, plus an additional $60 million upfront payment from Alcon received after quarter-end, providing ample liquidity for strategic initiatives.
- RxSight Inc (RXST) withdrew its full-year 2026 financial guidance, creating uncertainty about near-term performance and signaling potential strategic changes.
- Second quarter product sales declined 19% year-over-year, reflecting heightened competitive trialing and broader marketplace headwinds.
- LAL unit volumes decreased 9% year-over-year, indicating slower adoption and utilization challenges.
- Gross margin (excluding collaboration revenue) fell to 71.2% from 74.9% in the prior-year period, due to higher inventory-related costs from slower inventory flow-through.
- The company faces ongoing competitive activity, product trialing, and typical Q3 seasonality, which are expected to influence performance negatively through the remainder of the year.
Thank you for standing by, and welcome to the RxSight second quarter 2026 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speakerâs remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the conference over to Oliver Moravcevic, VP of Investor Relations. Please go ahead.
Thank you, operator. With me on the call today are RxSight President and Chief Executive Officer, Aziz Mottiwala, and Chief Financial Officer, Mark Wilterding. Earlier today, RxSight released financial results for the three months ended June 30th, 2026. A copy of the press release is available on the companyâs website. Before we begin, I would like to remind you that comments and responses to questions during todayâs call reflect managementâs views as of today and will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
